FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988335780> ?p ?o ?g. }

• W1988335780 endingPage "246" @default.
• W1988335780 startingPage "238" @default.
• W1988335780 abstract "The outcome of advanced ovarian cancer patients has not significantly improved since the introduction of platinum. One of the major reasons for this failure is the lack of an effective second-line treatment. In this phase II trial we tested the combination of gemcitabine and etoposide in 2 different groups of patients. Group 1 consisted of patients showing disease progression or relapse within 6 months of first-line platinum-based chemotherapy. Group 2 comprised heavily pretreated patients showing progression during the last chemotherapy attempt.Thirty-four patients were enrolled. Gemcitabine was administered at a dose of 1,000 mg/m(2) on days 1 and 8 and etoposide was administered orally at 100 mg/day on days 8-12 for 6 courses.Eighteen patients (52.9%) had an objective response and the median duration of the response was 10.3 months. Our chemotherapy regimen showed a low toxicity and good patient compliance. In 5 patients the treatment had to be delayed and in only 2 patients it was discontinued.The combination of gemcitabine and oral etoposide seems to be a safe and effective second-line treatment for platinum-resistant ovarian cancer patients. Additional data on larger series are warranted to better define the activity of this combination regimen." @default.
• W1988335780 created "2016-06-24" @default.
• W1988335780 creator A5004375962 @default.
• W1988335780 creator A5020137513 @default.
• W1988335780 creator A5020377111 @default.
• W1988335780 creator A5028725821 @default.
• W1988335780 creator A5042137062 @default.
• W1988335780 creator A5043044349 @default.
• W1988335780 creator A5070738538 @default.
• W1988335780 creator A5074626083 @default.
• W1988335780 creator A5085326503 @default.
• W1988335780 creator A5086029532 @default.
• W1988335780 date "2011-01-01" @default.
• W1988335780 modified "2023-10-14" @default.
• W1988335780 title "Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study" @default.
• W1988335780 cites W1543697093 @default.
• W1988335780 cites W1902459117 @default.
• W1988335780 cites W1939163116 @default.
• W1988335780 cites W1945760023 @default.
• W1988335780 cites W1960327677 @default.
• W1988335780 cites W1966354133 @default.
• W1988335780 cites W1971445820 @default.
• W1988335780 cites W1978553014 @default.
• W1988335780 cites W1981099237 @default.
• W1988335780 cites W1985953095 @default.
• W1988335780 cites W2002804156 @default.
• W1988335780 cites W2003813442 @default.
• W1988335780 cites W2003870289 @default.
• W1988335780 cites W2010906875 @default.
• W1988335780 cites W2012675546 @default.
• W1988335780 cites W2016105809 @default.
• W1988335780 cites W2022030994 @default.
• W1988335780 cites W2026192389 @default.
• W1988335780 cites W2029409133 @default.
• W1988335780 cites W2052846363 @default.
• W1988335780 cites W2055763096 @default.
• W1988335780 cites W2058501021 @default.
• W1988335780 cites W2066813372 @default.
• W1988335780 cites W2077422971 @default.
• W1988335780 cites W2092569103 @default.
• W1988335780 cites W2119148287 @default.
• W1988335780 cites W2154737435 @default.
• W1988335780 cites W4235602651 @default.
• W1988335780 cites W4242969268 @default.
• W1988335780 doi "https://doi.org/10.1159/000328451" @default.
• W1988335780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21734415" @default.
• W1988335780 hasPublicationYear "2011" @default.
• W1988335780 type Work @default.
• W1988335780 sameAs 1988335780 @default.
• W1988335780 citedByCount "8" @default.
• W1988335780 countsByYear W19883357802013 @default.
• W1988335780 countsByYear W19883357802015 @default.
• W1988335780 countsByYear W19883357802016 @default.
• W1988335780 countsByYear W19883357802017 @default.
• W1988335780 countsByYear W19883357802018 @default.
• W1988335780 countsByYear W19883357802020 @default.
• W1988335780 crossrefType "journal-article" @default.
• W1988335780 hasAuthorship W1988335780A5004375962 @default.
• W1988335780 hasAuthorship W1988335780A5020137513 @default.
• W1988335780 hasAuthorship W1988335780A5020377111 @default.
• W1988335780 hasAuthorship W1988335780A5028725821 @default.
• W1988335780 hasAuthorship W1988335780A5042137062 @default.
• W1988335780 hasAuthorship W1988335780A5043044349 @default.
• W1988335780 hasAuthorship W1988335780A5070738538 @default.
• W1988335780 hasAuthorship W1988335780A5074626083 @default.
• W1988335780 hasAuthorship W1988335780A5085326503 @default.
• W1988335780 hasAuthorship W1988335780A5086029532 @default.
• W1988335780 hasConcept C121608353 @default.
• W1988335780 hasConcept C126322002 @default.
• W1988335780 hasConcept C141071460 @default.
• W1988335780 hasConcept C143998085 @default.
• W1988335780 hasConcept C2776694085 @default.
• W1988335780 hasConcept C2778119113 @default.
• W1988335780 hasConcept C2778239845 @default.
• W1988335780 hasConcept C2780258809 @default.
• W1988335780 hasConcept C2780427987 @default.
• W1988335780 hasConcept C2781413609 @default.
• W1988335780 hasConcept C2781451048 @default.
• W1988335780 hasConcept C71924100 @default.
• W1988335780 hasConceptScore W1988335780C121608353 @default.
• W1988335780 hasConceptScore W1988335780C126322002 @default.
• W1988335780 hasConceptScore W1988335780C141071460 @default.
• W1988335780 hasConceptScore W1988335780C143998085 @default.
• W1988335780 hasConceptScore W1988335780C2776694085 @default.
• W1988335780 hasConceptScore W1988335780C2778119113 @default.
• W1988335780 hasConceptScore W1988335780C2778239845 @default.
• W1988335780 hasConceptScore W1988335780C2780258809 @default.
• W1988335780 hasConceptScore W1988335780C2780427987 @default.
• W1988335780 hasConceptScore W1988335780C2781413609 @default.
• W1988335780 hasConceptScore W1988335780C2781451048 @default.
• W1988335780 hasConceptScore W1988335780C71924100 @default.
• W1988335780 hasIssue "3-4" @default.
• W1988335780 hasLocation W19883357801 @default.
• W1988335780 hasLocation W19883357802 @default.
• W1988335780 hasOpenAccess W1988335780 @default.
• W1988335780 hasPrimaryLocation W19883357801 @default.
• W1988335780 hasRelatedWork W1565683009 @default.
• W1988335780 hasRelatedWork W190758288 @default.

• next